Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge

A Ruggiero, E Camela, L Potestio… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Psoriasis is a chronic inflammatory skin disease that may have an important
negative impact on a patient's quality of life. Biological agents deeply changed the …

Nanoemulsions: A review on the conceptualization of treatment for psoriasis using a 'green'surfactant with low-energy emulsification method

IJ Dinshaw, N Ahmad, N Salim, BF Leo - Pharmaceutics, 2021 - mdpi.com
Psoriasis is a skin disease that is not lethal and does not spread through bodily contact.
However, this seemingly harmless condition can lead to a loss of confidence and social …

Clinical improvement in psoriasis with specific targeting of interleukin-23

T Kopp, E Riedl, C Bangert, EP Bowman… - Nature, 2015 - nature.com
Psoriasis is a chronic inflammatory skin disorder that affects approximately 2–3% of the
population worldwide and has severe effects on patients' physical and psychological well …

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis

M Kutwin, M Migdalska-Sęk… - Journal of Clinical …, 2021 - mdpi.com
Being one of the most common dermatological inflammatory disorders, psoriasis is a
frequent subject of research. It is considered to be a T cell-dependent immune disease …

[HTML][HTML] A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions

SN Khalid, ZA Khan, MH Ali, T Almas, T Khedro… - Annals of Medicine and …, 2021 - Elsevier
Bullous pemphigoid (BP) is a severe autoimmune blistering skin disorder that primarily
causes disease in the older population and is the most prevalent subepidermal variant of the …

Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712

E Breinlinger, S Van Epps, M Friedman… - Journal of Medicinal …, 2023 - ACS Publications
Tyrosine kinase 2 (TYK2) is a nonreceptor tyrosine kinase that belongs to the JAK family
also comprising JAK1, JAK2, and JAK3. TYK2 is an attractive target for various autoimmune …

An updated guide in the management of psoriasis for every practitioner

TL Timis, IA Florian, SC Vesa… - … Journal of Clinical …, 2021 - Wiley Online Library
Background Psoriasis is one of the most common chronic cutaneous skin disorders, having
genetic and immunological components. It is currently unknown what exactly triggers it, or …

The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options

HA Patel, RR Revankar, ST Pedroza… - International Journal of …, 2023 - mdpi.com
Understanding the factors creating genetic susceptibility in psoriasis may provide a basis for
improving targeted treatment strategies. In this review, we discuss the genes linked to the …

A review of the efficacy and safety for biologic agents targeting IL-23 in treating psoriasis with the focus on tildrakizumab

FM Ghazawi, F Mahmood, L Kircik, Y Poulin… - Frontiers in …, 2021 - frontiersin.org
Psoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several
cytokines including interleukin (IL)-23 were demonstrated to play a central role in the …

Risk of serious infection associated with agents that target T-cell activation and interleukin-17 and interleukin-23 cytokines

S Shoor - Infectious Disease Clinics, 2020 - id.theclinics.com
Tumor necrosis factor (TNF) inhibitors, the first biological immunomodulators, bind TNF
glycoprotein, the receptor of which is present in numerous immune and tissuespecific cells …